Redeye Feed

2024-09-03 15:58:00 Serial acquirers Q2 2024 - Comparing ROIC on an apples-to-apples basis

2024-09-03 15:56:00 Serial acquirers Q2 2024 - Comparing ROIC on an apples-to-apples basis

2024-09-03 15:55:00 Serial acquirers Q2 2024 - Comparing ROIC on an apples-to-apples basis

2024-09-03 15:54:00 Serial acquirers Q2 2024 - Comparing ROIC on an apples-to-apples basis

2024-09-03 15:53:00 Serial acquirers Q2 2024 - Comparing ROIC on an apples-to-apples basis

2024-09-03 15:52:00 Serial acquirers Q2 2024 - Comparing ROIC on an apples-to-apples basis

2024-09-03 15:47:00 Redeye IT Consulting Q2 2024 - Stabilised Market but Rebound Postponed

2024-09-03 15:46:00 Redeye IT Consulting Q2 2024 - Stabilised Market but Rebound Postponed

2024-09-02 12:02:00 Saniona Q2 - Continued progress, exciting autumn ahead

2024-09-02 09:28:00 Maximum Entertainment - Solid Q2-result, but continued high debt

2024-09-02 09:26:00 Redeye Initiates Coverage of Cheffelo

2024-09-02 09:21:00 Verve Group - Another strong quarter and more to come

2024-09-02 09:13:00 Circio H1 2024 - Collaborations now active

2024-09-02 09:07:00 Lifeclean Q2’2024 - Focus starts to pay off

2024-09-02 09:04:00 Systemair - Steady Progress

2024-08-30 12:23:00 BioInvent Q2 2024 - Positive Development with BI-1206 and BI-1808

2024-08-30 09:50:00 BioArctic Q2 - Solid momentum in Leqembi launch

2024-08-30 09:22:00 Xbrane Biopharma Q2 2024 - A fight against the clock

2024-08-30 09:20:00 Integrum Q1 - Disappointing quarter hurting the confidence

2024-08-30 09:18:00 GiG - SOP-valuation implies upside potential

2024-08-30 09:15:00 Sprint Bioscience Update - Robust sales and project activity

2024-08-29 19:19:00 Fluoguide Q2 2024 - Following the plan

2024-08-29 13:31:00 Lytix Q2 2024 - Verrica’s Phase II Data Changes the Case

2024-08-29 12:26:00 Scandion Oncology Q2 2024 - Partnership represents best hope

2024-08-29 11:05:00 AcouSort Q2 - A busy summer

2024-08-29 08:15:00 Cantargia Q2 2024 - CAN10 Proof-of-Mechanism

2024-08-28 11:26:00 Alzecure Q2 - Presented new data

2024-08-28 11:21:00 Lifecare Q2 2024 - High activity – initial positive signs from longevity trials

2024-08-28 07:44:00 Nekkar - H1 Review – Uncovers Hidden Values

2024-08-28 07:43:00 Lipigon Q2 2024 - Marea Launched

2024-08-27 14:31:00 Faron Pharmaceuticals H1 - Turbulent times behind, promising times ahead

2024-08-27 10:34:00 PMD Solutions - PMD is approaching a cash-positive run rate before 2025

2024-08-27 10:31:00 Beyond Frames - Two significant game launches in H2

2024-08-27 08:03:00 Heliospectra - H1 completed with solid order intake, high expectations for H2

2024-08-26 15:50:00 Curasight Q2 - Strategic progress

2024-08-26 09:47:00 Acarix Q2 2024 - Soft revenues but keeps progressing

2024-08-26 08:13:00 Kancera - Progress according to plan

2024-08-26 08:12:00 Navigo Invest Q2 2024 - Recovery in sight

2024-08-26 08:10:00 Impact Coatings - Making firm progress

2024-08-26 08:06:00 I-Tech - Q2 Review – Standing Strong

2024-08-26 08:05:00 AVTECH - Solid performance, positive outlook

2024-08-26 08:02:00 InfraCom - Throwing the baby out with the bathwater

2024-08-26 07:59:00 CLS Q2 - A quarter in line with our expectations

2024-08-26 07:56:00 Teneo AI - Positive Outlook into H2 and 2025

2024-08-23 15:28:00 Mendus Q2 2024 - Catalysts are coming closer, solid funding position

2024-08-23 12:08:00 Initiator Pharma Q2 - Silent advancements

2024-08-23 12:06:00 BrightBid - The Streamlined Organization Lowers the Profitability Bar

2024-08-23 12:02:00 Egetis Therapeutics Q2 - Eventful quarter

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden